Agenda

2024 Meeting Agenda

The 2024 Cell & Gene Meeting on the Med was delivered in a hybrid format with live programming available over the course of two days at the Rome Cavalieri. Virtual registrants had access to all content via livestream during the program dates. Additionally, all content was made available on-demand within 24 hours of the live program time for all registrants to view.

Agenda Sponsors:

2024 Agenda at a Glance

Live Event Dates

12:00pm – 5:00pm Badge Pick-up in the Rome Cavalieri Lobby (All Attendees)

Time TBD ARM Board of Directors Meeting (By Invitation Only)

7:30am – 9:00am Registration
9:00am – 6:00pm General Session, Panel Discussions, Company Presentations, Workshops and Partnering Meetings
6:00pm – 8:00pm Networking Bash

7:30am – 9:00am Registration
9:00am – 6:00pm General Session, Panel Discussions, Company Presentations, Workshops and Partnering Meetings
6:00pm – 7:00pm Cocktail Reception

7:30am – 9:00am Registration
9:00am – 12:00pm General Session, Panel Discussions, Company Presentations, Workshops and Partnering Meetings
12:00pm – 1:00pm Closing Lunch

Virtual Partnering Dates

12:00am - 11:59pm Virtual Partnering Meetings

12:00am - 11:59pm Virtual Partnering Meetings

2024 Meeting Agenda

  • Full Agenda

7:30am – 9:00am | REGISTRATION

8:00am | PARTNERING OPENS

9:00am | GENERAL SESSION

WELCOME REMARKS

{Salone dei Cavalieri, Section 3&4}

9:00am – 9:15am

Speakers:

Tim Hunt, CEO, Alliance for Regenerative Medicine (ARM)

Devyn Smith, Ph.D., CEO, Arbor Biotechnologies; Chairman, Alliance for Regenerative Medicine (ARM)

9:15am – 10:45am | CONCURRENT TRACKS

FIRESIDE CHAT: LUCY ELLERKER, FOUNDER, OPIE JONES FOUNDATION
{Salone dei Cavalieri, Section 3&4}

9:15am – 9:45am

Chair:

Bob Smith, Vice-Chair, Alliance for Regenerative Medicine (ARM)

Speaker:

Lucy Ellerker-Jones, Founder, Opie Jones Foundation

COMPANY PRESENTATIONS
{Salone dei Cavalieri, Section 2}

9:15am – 9:30amCGT Catapult
9:30am – 9:45amTrakCel

CAR-T: A DEMI-DECADE IN THE REAL WORLD

{Salone dei Cavalieri, Section 3&4}

9:45am – 10:45am
This panel will reflect on the remarkable journey of CAR-T therapies over the past five years, exploring their impact on patients in real-world scenarios. Our expert panelists will highlight clinical data and share positive outcomes observed with commercial CAR-T products. Discover the tangible benefits these therapies have brought to the broader patient community thus far and gain valuable insights into what the future holds for CAR-T advancements.

Moderator:

Delara Motlagh, Ph.D., Head of Global Cell Therapy, Catalent

Speakers:

Robert Ang, M.D., President and CEO, Vor Bio

Christian Chabannon, M.D., Ph.D., Head and QP, Centre de Thérapie Cellulaire, Institut Paoli-Calmettes, Comprehensive Cancer

Emil Cochino, M.D., Scientific Senior Specialist (Risk Management), Advanced Therapies and Haematological Diseases, EMA

Lucy Ellerker-Jones, Founder, Opie Jones Foundation

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

9:45am – 10:00amAspect Biosystems
10:00am – 10:15amVivet Therapeutics
10:15am – 10:30amIN8bio
10:30am – 10:45amSernova

10:45am – 11:15am | MORNING BREAK

Sponsored by Anocca

11:15am – 12:15pm | CONCURRENT TRACKS

SCIENCE SLAM: NEW FRONTIERS IN IMMUNO-ONCOLOGY FOR SOLID TUMOR TREATMENT

{Salone dei Cavalieri, Sections 3&4}

11:15am – 12:15pm

Moderator:

Lung-I Cheng, Ph.D., Vice President, Head of Cell and Gene Therapy Service Line, Cencora

Speakers:

Madan Jagasia, M.D., CEO, Obsidian Therapeutics

Reagan Jarvis, Ph.D., CEO and Scientific Founder, Anocca

Tom Wilton, Chief Business Officer, Carisma Therapeutics

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

11:15am – 11:30amL7 Informatics
11:30am – 11:45amGENETHON
11:45am – 12:00pmCoJourney
12:00pm – 12:15pmImmPACT Bio

12:15pm – 1:30pm | LUNCH

1:30pm – 3:15pm | CONCURRENT TRACKS

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 3&4}

1:30pm – 1:45pmMeiraGTx
1:45pm – 2:00pmAdverum Biotechnologies
2:00pm – 2:15pmMaxCyte

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

1:30pm – 1:45pmStimuliver
1:45pm – 2:00pmAccelerated Biosciences
2:00pm – 2:15pmArbor Biotechnologies

ETHICS IN GENE AND CELL THERAPY
{Salone dei Cavalieri, Section 3&4}

2:15pm – 3:15pm

Moderator:

Tim Hunt, CEO, Alliance for Regenerative Medicine (ARM)

Speakers:

Kevin FitzGerald, S.J., Ph.D., Chair, Department of Medical Humanities, Associate Professor, Creighton University

Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult

Francesca Pasinelli, Managing Director, Fondazione Telethon

Tay Salimullah, Vice President, Head Global Value and Access, Novartis Gene Therapies

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

2:15pm – 2:30pmEntos Pharmaceuticals
2:30pm – 2:45pmKiji Therapeutics
2:45pm – 3:00pmCarisma Therapeutics
3:00pm – 3:15pmVERIGRAFT AB

3:15pm – 3:45pm | AFTERNOON BREAK

Sponsored by Anocca

3:45pm – 5:15pm | CONCURRENT TRACKS

THE EU JOINT HEALTH TECHNOLOGY ASSESSMENT: A FIT FOR PURPOSE JCA?

{Salone dei Cavalieri, Section 3&4}

3:45pm – 4:45pm
This panel will delve into the anticipated impact of the JCA on the ATMP sector in Europe in 2025 and beyond. Speakers will examine strategies for crafting compelling evidence for regulators and HTAs, assess if the European HTA coordination is going to simplify or complicate things, and scrutinize whether national Pricing and Reimbursement bodies will effectively access the necessary information from the JCA.

Moderator:

Miguel Forte, M.D., Ph.D., CEO, Kiji Therapeutics

Speakers:

Alessandro Aiuti, M.D., Ph.D., Deputy Director Clinical Research, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan; Professor of Pediatrics, Vita-Salute San Raffaele University, Milan

Loris Brunetta, Founding Board Member, Thalassaemia International Federation (TIF)

Rui Ivo, Pharm.D., President of National Authority of Medicines and Healthcare Products (INFARMED), Portugal

Marco Marchetti, M.D., Director, Health Technology Assessment, AGENAS

Francis Pang, Senior Vice President, Global Market Access and Geographic Expansion, Orchard Therapeutics

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

3:45pm – 4:00pmRoslinCT
4:00pm – 4:15pmNovartis
4:15pm – 4:30pmLaverock Therapeutics
4:30pm – 4:45pmTreeFrog Therapeutics

FEATURED KEYNOTE SPEAKER: DR. MASSIMO DOMINICI

{Salone dei Cavalieri, Section 3&4}

4:45pm – 5:15pm

Keynote:

Massimo Dominici, M.D., Full Professor, Medical Oncology, Università degli Studi di Modena e Reggio Emilia

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

4:45pm – 5:00pmGeneFab
5:00pm – 5:15pmSensorion

5:15pm – 6:00pm | CLOSING WORKSHOP

A FORECAST ON THE 2024 CGTX LANDSCAPE

Sponsored by Precision for Medicine
{Salone dei Cavalieri, Section 3&4}

5:15pm – 6:00pm

Moderator:

Anshul Mangal, President, Project Farma and Precision ADVANCE

Speakers:

Igor Bilinsky, Ph.D., Chief Operating Officer, Iovance Biotherapeutics

Phil Cyr, Senior Vice President, Precision Value & Health

Doug Danison, Head of Commercial, Cell and Gene Therapy Unit, Bayer

Stefan Irion, M.D., Chief Scientific Officer, BlueRock Therapeutics

Helen Sabzevari, Ph.D., President and CEO, Precigen

6:00pm | PROGRAM AND PARTNERING CLOSES

6:00pm – 8:00pm | NETWORKING BASH

Sponsored by Aseptic Technologies and Dark Horse Consulting

7:30am – 9:00am | REGISTRATION

8:00am | PARTNERING OPENS

9:00am | GENERAL SESSION

ARM STRATEGIC INITIATIVES

{Salone dei Cavalieri, Section 3&4}

9:00am – 9:15am

Speaker:

Rita Johnson-Greene, Chief Operating Officer, Alliance for Regenerative Medicine (ARM)

COMPANY PRESENTATION

{Salone dei Cavalieri, Section 2}

9:00am – 9:15amQuTEM

9:15am – 10:15am | CONCURRENT TRACKS

STRATEGIC INVESTMENT PERSPECTIVES IN THE EVOLVING EUROPEAN AND GLOBAL ATMP LANDSCAPE
{Salone dei Cavalieri, Section 3&4}

9:15am – 10:15am

This panel will aim to offer a comprehensive exploration of the present investment landscape within the ATMP sector. Attendees will gain insights into the current state of investments and witness a dynamic discussion on how investors are strategically adjusting to the ever-changing financial terrain. This session will provide valuable perspectives on navigating challenges and seizing opportunities within this rapidly evolving investment ecosystem.

Moderator:

Phil Vanek, Ph.D., Partner and Chief Technology Officer, Gamma Biosciences

Speakers:

Lucia Faccio, Ph.D., Partner, Sofinnova Partners

Sven Kili, Investment Advisor, Saisei Ventures

Philipp Pletnev, Ph.D., Senior Analyst, Biovision Ventures

Bo Wiinberg, Ph.D., Chief Business Development Officer, Novo Nordisk Foundation Cellerator

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

9:15am – 9:30amSK Pharmteco
9:30am – 9:45amCTI
9:45am – 10:00amSolid Biosciences
10:00am – 10:15amAldevron

10:15am – 10:45am | MORNING BREAK

Sponsored by Anocca

10:45am – 12:15pm | CONCURRENT TRACKS

SCIENCE SLAM: ADVANCES IN TARGETING AUTOIMMUNE DISEASE

{Salone dei Cavalieri, Section 3&4}

10:45am – 11:45am

Moderator:

Farzin Farzaneh, Ph.D., Chief Scientific Officer, ViroCell

Speakers:

Benjamin Dewees, Vice President, Regulatory Affairs and Quality, Kyverna Therapeutics

Sumant Ramachandra, M.D., Ph.D., CEO, ImmPACT Bio

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

10:45am – 11:00amVesigen Therapeutics
11:00am – 11:15amSplice Bio
11:15am – 11:30amAllarta Life Science
11:30am – 11:45amForge Biologics

FIRESIDE CHAT: THE PATIENT ACCESS ENVIRONMENT FOR ATMPS IN EUROPE – THE ROLE OF EVIDENCE GENERATION

{Salone dei Cavalieri, Section 3&4}

11:45am – 12:15pm

Moderator:

Mark Battaglini, Chief Strategy Officer, Alliance for Regenerative Medicine (ARM)

Speaker:

Loris Brunetta, Founding Board Member, Thalassaemia International Federation (TIF)

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

11:45am – 12:00pmCellistic
12:00pm – 12:15pmBlueRock Therapeutics

12:15pm – 1:15pm | LUNCH

1:15pm – 2:45pm | CONCURRENT TRACKS

INNOVATIVE PAYMENT SOLUTIONS – RECENT LEARNINGS FROM GENE THERAPY LAUNCHES

{Salone dei Cavalieri, Section 3&4}

1:15pm – 2:15pm
Attendees will gain valuable insights into the latest strategies employed in successfully introducing gene therapies to the market, including innovative payment models and emerging best practices. The discussion will not only spotlight recent successes but also explore the pursuit of sustainability and the development of new models that shape the future of gene therapy launches.

Moderator:

Paolo Morgese, Vice President of Public Affairs, Europe, Alliance for Regenerative Medicine (ARM)

Speakers:

Stefano Benvenuti, Head of Public Affairs, Fondazione Telethon

Matt Bolz-Johnson, Mental Wellbeing Lead & Healthcare Advisor, EURORDIS-Rare Diseases Europe

Americo Cicchetti, Director General Health Planning, Italian Ministry of Health

Dilip Patel, Vice President, Market Access, Autolus

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

1:15pm – 1:30pmCryoport Systems
1:30pm – 1:45pmAviadoBio
1:45pm – 2:00pmCoave Therapeutics
2:00pm – 2:15pmSparingVision

SPOTLIGHT SESSION: TISSUE REPAIR AND REGENERATION – REFLECTING ON PROGRESS FOR NOVEL TISSUE THERAPEUTICS

{Salone dei Cavalieri, Section 3&4}

2:15pm – 2:45pm

Moderator:

Jeff Ross, Ph.D., President, Miromatrix a United Therapeutics Company

Speakers:

Petter Björquist, Ph.D., CEO, VERIGRAFT

Don Fink, Ph.D., Master Practice Expert, Regulatory, Dark Horse Consulting

Tom Lowery, Ph.D., President and Chief Technology Officer, Satellite Bio

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

2:15pm – 2:30pmAnocca
2:30pm – 2:45pmPrecigen

2:45pm – 3:15pm | AFTERNOON BREAK

Sponsored by Anocca

3:15pm – 5:15pm | CONCURRENT TRACKS

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 3&4}

3:15pm – 3:30pmAstellas Pharma
3:30pm – 3:45pmRocket Pharmaceuticals
3:45pm – 4:00pmuniQure
4:00pm – 4:15pmAutolus

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

3:15pm – 3:30pmSmartCella
3:30pm – 3:45pmVor Bio
3:45pm – 4:00pmPolTREG
4:00pm – 4:15pmRay Therapeutics

THE FUTURE OF GENETIC MEDICINE

{Salone dei Cavalieri, Section 3&4}

4:15pm – 5:15pm
Driven by technological and scientific advances, the landscape of genetic medicine is rapidly changing. This session will discuss the current state, future technologies and innovations, and solutions for manufacturing and regulatory bottlenecks as new genetic medicines move towards the clinic.

Moderator:

Nina Bauer, Ph.D., Chief Business Officer, SmartCella

Speakers:

Behnam Baghbaderani, Ph.D., Vice President, Global Head of Commercial and Program Management, Lonza

Lisa Deschamps, CEO, AviadoBio

Kinnari Patel, Pharm.D., President and Chief Operating Officer, Rocket Pharma

David Venables, Ph.D., CEO, Laverock Therapeutics

Richard Wilson, Senior Vice President, Primary Focus Lead, Genetic Regulation, Astellas Pharma

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

4:15pm – 4:30pmSatellite Biosciences
4:30pm – 4:45pmObsidian Therapeutics
4:45pm – 5:00pmStemSight
5:00pm – 5:15pmNanite

5:15pm – 6:00pm | CLOSING WORKSHOP

REDEFINING THE GLOBAL REGULATORY LANDSCAPE FOR ATMP COMMERCIAL APPROVAL – ONE APPROVAL TO RULE THEM ALL

Sponsored by Charles River Labs
{Salone dei Cavalieri, Section 3&4}

5:15pm – 6:00pm

Moderator:

Matthew Hewitt, Ph.D., Vice President, Technical Officer CGT and Biologics, Charles River Laboratories

Speakers:

Jean-Philippe Combal, Pharm.D., Ph.D., Co-founder and CEO, Vivet Therapeutics

Mike Lehmicke, Senior Vice President , Science and Industry Affairs, Alliance for Regenerative Medicine (ARM)

Devyn Smith, Ph.D., CEO, Arbor Biotechnologies; Chairman, Alliance for Regenerative Medicine (ARM)

Richard Wilson, Senior Vice President, Primary Focus Lead, Genetic Regulation, Astellas Pharma

6:00pm | PROGRAM AND PARTNERING CLOSES

6:00pm – 7:00pm | COCKTAIL RECEPTION

Sponsored by Catalent

7:30am – 9:00am | REGISTRATION

8:00am | PARTNERING OPENS

9:00am | GENERAL SESSION

PATIENT VIDEOS: THE TRANSFORMATIVE POWER OF GENE THERAPY

{Salone dei Cavalieri, Section 3&4}

9:00am – 9:15am

COMPANY PRESENTATION

{Salone dei Cavalieri, Section 2}

9:00am – 9:15amAdvanced Medicine Partners

9:15am – 10:45am | CONCURRENT TRACKS

TRANSLATING EARLY RESEARCH INTO PROMISING NEW ATMPS FOR PATIENTS THROUGH PUBLIC-PRIVATE PARTNERSHIPS
{Salone dei Cavalieri, Section 3&4}

9:15am – 9:45am
This session will shine the spotlight on European public-private partnership initiatives for ATMPs and why they can play an important role in accelerating patient access to innovative therapies.

Moderator:

Petter Björquist, Ph.D., CEO, VERIGRAFT

Speakers:

Elsa Abranches, Ph.D., Senior Director, Head of Cell Therapy Bioprocess Development and Manufacturing, BioPharmaceuticals R&D, AstraZeneca

Elias Uhlin, Ph.D., Project Manager, Cell and Gene Therapy, Pre- GMP Facility, Lund University

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

9:15am – 9:30amWacker Biotech
9:30am – 9:45amMekonos

INNOVATIVE APPROACHES: DECENTRALIZED MANUFACTURING OF ATMPS
{Salone dei Cavalieri, Section 3&4}

9:45am – 10:45am
Cell therapy manufacturing today is dominated by the centralized model, leading to clinical success and commercialization of CAR-T products. The need for broader patient access to these therapies has driven a decentralized / point-of-care manufacturing approach. This panel aims to discuss scientific, technical, logistical, quality, and regulatory challenges that need to be addressed to make DM/POC cell therapy manufacturing a reality.

Moderator:

Daniel Palmacci, President, Cell and Gene Division, Lonza

Speakers:

Jason Foster, CEO, Ori Biotech

Fabian Gerlinghaus, Co-Founder and CEO, Cellares

Carol Houts, Chief Strategy Officer, Germfree

Christopher Vann, Chief Operating Officer, Autolus

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

9:45am – 10:00amAntion Biosciences
10:00am – 10:15amViroCell Biologics
10:15am – 10:30amExo Biologics
10:30am – 10:45amAvectas

10:45am – 11:00am | MORNING BREAK

Sponsored by Anocca

11:00am – 12:00pm | CONCURRENT TRACKS

DEVELOPING THE ATMP ECOSYSTEM OF THE FUTURE
{Salone dei Cavalieri, Section 3&4}

11:00am – 12:00pm

Join our discussion on overcoming regulatory and policy challenges at both European and national levels, as industry experts share insights on fortifying the foundation of ATMPs in the European landscape.

Moderator:

Nitin Mahadev, Global Head of Gene Therapy Marketing, Pfizer

Speakers:

Barbara D’Alessio, Board Member, UNIAMO Federazione Italiana Malattie Rare

Jim Lund, Ph.D., Chief Business Development Officer, CCRM Nordic

Marcello Milano, Director, Global R&D and Regulatory Policy, BioMarin

Ilona Reischl, Austrian Medicines and Medical Devices Agency, National Expert of the EMA Committee for Advanced Therapies (CAT)

COMPANY PRESENTATIONS

{Salone dei Cavalieri, Section 2}

11:00am – 11:15amPhase Holographic Imaging
11:15am – 11:30amInvetech
11:30am – 11:45amAurion Biotech
11:45am – 12:00pmC3i Center

12:00pm – 1:00pm | CLOSING LUNCH

By using this website you agree to accept our Privacy Policy and Terms & Conditions